Volumetric Radiosurgery for 1 to 10 Brain Metastases: A Multicenter, Single-Arm, Phase 2 Study
Alan Nichol(BC Cancer Agency), Michael McKenzie(Provincial Health Services Authority), François Germain(BC Cancer Agency), Hannah Carolan(BC Cancer Agency), Alanah Bergman(BC Cancer Agency), Robert Olson(BC Cancer Agency), Lovedeep Gondara(BC Cancer Agency), Roy Ma(BC Cancer Agency), Arthur Cheung(BC Cancer Agency), Fred Hsu(BC Cancer Agency), Devin Schellenberg(Surrey Place Centre), Michael Peacock(BC Cancer Agency), Rosemin Vellani(BC Cancer Agency), E. Vollans(BC Cancer Agency)
International Journal of Radiation Oncology*Biology*Physics
October 25, 2015
Cited by 58
Related Papers
Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial
|The Lancet|2019|1.9k
Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers: Long-Term Results of the SABR-COMET Phase II Randomized Trial
|Journal of Clinical Oncology|2020|1.3k
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2016|736
Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy
|International Journal of Radiation Oncology*Biology*Physics|2008|532
ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer
|International Journal of Radiation Oncology*Biology*Physics|2017|319